Skip to main
HSCS
HSCS logo

HSCS Stock Forecast & Price Target

HSCS Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

HeartSciences Inc. has raised its fiscal year 2026 earnings per share estimate to $(4.17), a substantial improvement from the previous estimate of $(8.63), indicating a positive shift in financial expectations. The anticipated approval of the MyoVista device, along with the rollout of the MyoVista Insights cloud software platform and the expected FDA approval of its first diagnostic algorithm by the first half of 2026, highlights the company's potential for significant market expansion. The company is affirming its regulatory timing, suggesting that it is well-positioned for large-scale opportunities in the emerging AI-driven cardiac screening market.

Bears say

HeartSciences Inc faces significant risks that negatively impact its stock outlook, including liquidity challenges, the inability of product candidates to prove safety and efficacy in clinical trials, and hurdles in gaining necessary regulatory approvals. Additionally, the company's projected revenue for FY2026 has been drastically reduced from $1.2 million to $0.1 million due to delays associated with FDA processes, indicating potential setbacks in commercialization. Compounding these issues are broader concerns related to market competition and fluctuating investor sentiment towards healthcare investments, which may further inhibit financial stability and growth prospects.

HSCS has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Heart Test Laboratories Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Heart Test Laboratories Inc (HSCS) Forecast

Analysts have given HSCS a Strong Buy based on their latest research and market trends.

According to 2 analysts, HSCS has a Strong Buy consensus rating as of Dec 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Heart Test Laboratories Inc (HSCS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.